SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System
1 references·3 citing·17 second hop
Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System (2019)Estimating the Clinical Pipeline of Cell …The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal (2017)The assessment and appraisal …Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues (2021)Durable cell and gene therapy…Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions (2020)Market access of gene therapi…HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies (2020)HTA methodology and value fra…Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)The green book : appraisal and evaluation in central government (2003)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare (2018)Managed Entry Agreements: Policy Analysis From the European Perspective (2020)Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries (2020)Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2 (2011)Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1 (2011)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel (2021)What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks (2021)Real World Data in Health Technology Assessment of Complex Health Technologies (2022)Advanced therapy medicinal products: current and future perspectives (2016)Overcoming Challenges Facing Advanced Therapies in the EU Market (2016)Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] (2018)Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model (2012)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)
this work references cited by second hop

References

  • 2017The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal126 cited

Cited by

  • 2020HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies71 cited
  • 2020Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions53 cited
  • 2021Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues47 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work